Age Labs has developed EPIPHANY, a proprietary machine learning-based biomarker discovery platform. Using EPIPHANY, we can measure the regulatory domains of 99% of the human genome. This allows us to create rich epigenetic profiles, quantifying gene activation both ahead of and in response to diseases and drug exposures, and develop biomarkers for early detection of diseases and drug response prediction.
Our unique database of epigenetic profiles, coupled with extensive health data from renowned biobanks, supports our focus on aging and immunology. We have a comprehensive pipeline of biomarkers under development. Our first diagnostic candidate is an advanced test for early detection of rheumatoid arthritis.
Rheumatoid arthritis affects about 1% of the world’s population and can cause permanent joint damage and disability. Clinicians today need better diagnostic tests that catch the disease earlier and help guide treatment.
The project is a collaboration with Diakonhjemmet Hospital, Fürst Medical Laboratory, the Norwegian Institute of Public Health, and Oslo University Hospital Rikshospitalet.